23ANDME HOLDING CO -CLASS A(NASDAQ:ME) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to ME. ME was compared to 108 industry peers in the Health Care Providers & Services industry. While ME seems to be doing ok healthwise, there are quite some concerns on its profitability. ME has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ME has reported negative net income.

ME had a negative operating cash flow in the past year.

In the past 5 years ME always reported negative net income.

ME had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -192.93%, ME is doing worse than 96.26% of the companies in the same industry.

ME's Return On Equity of -603.67% is on the low side compared to the rest of the industry. ME is outperformed by 88.78% of its industry peers.

		Industry Rank	Sector Rank
ROA	-192.93%
ROE	-603.67%
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ME has a Gross Margin of 46.51%. This is in the better half of the industry: ME outperforms 73.83% of its industry peers.

In the last couple of years the Gross Margin of ME has remained more or less at the same level.

ME does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	46.51%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.93%

GM growth 5Y0.67%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ME does not have a ROIC to compare to the WACC, probably because it is not profitable.

There is no outstanding debt for ME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -11.98, we must say that ME is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of ME (-11.98) is worse than 91.59% of its industry peers.

ME has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-11.98

ROIC/WACCN/A

WACC9.06%

2.3 Liquidity

ME has a Current Ratio of 1.24. This is a normal value and indicates that ME is financially healthy and should not expect problems in meeting its short term obligations.

ME's Current ratio of 1.24 is on the low side compared to the rest of the industry. ME is outperformed by 64.49% of its industry peers.

ME has a Quick Ratio of 1.14. This is a normal value and indicates that ME is financially healthy and should not expect problems in meeting its short term obligations.

ME's Quick ratio of 1.14 is on the low side compared to the rest of the industry. ME is outperformed by 62.62% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.24
Quick Ratio	1.14

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ME shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -29.41%.

ME shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -28.48%.

Measured over the past years, ME shows a very negative growth in Revenue. The Revenue has been decreasing by -13.01% on average per year.

EPS 1Y (TTM)-29.41%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-1347.49%

Revenue 1Y (TTM)-28.48%

Revenue growth 3Y-3.43%

Revenue growth 5Y-13.01%

Sales Q2Q%-11.86%

3.2 Future

The Earnings Per Share is expected to grow by 25.35% on average over the next years. This is a very strong growth

The Revenue is expected to grow by 19.08% on average over the next years. This is quite good.

EPS Next Y-329.17%

EPS Next 2Y-99.49%

EPS Next 3Y25.35%

EPS Next 5YN/A

Revenue Next Year22.44%

Revenue Next 2Y19.85%

Revenue Next 3Y5.77%

Revenue Next 5Y19.08%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ME. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ME's earnings are expected to grow with 25.35% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-99.49%

EPS Next 3Y25.35%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ME!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

23ANDME HOLDING CO -CLASS A

NASDAQ:ME (2/21/2025, 8:00:01 PM)

After market: 2.5 +0.08 (+3.31%)

2.42

-0.32 (-11.68%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Providers & Services

Earnings (Last)11-06 2024-11-06/amc

Earnings (Next)N/A N/A

Inst Owners24.69%

Inst Owner Change-99.96%

Ins Owners9.89%

Ins Owner Change37.84%

Market Cap64.93M

Analysts42

Price Target2.12 (-12.4%)

Short Float %6.9%

Short Ratio5.27

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-15.14%

Min Revenue beat(2)-24.62%

Max Revenue beat(2)-5.66%

Revenue beat(4)1

Avg Revenue beat(4)-10.14%

Min Revenue beat(4)-24.62%

Max Revenue beat(4)9.3%

Revenue beat(8)3

Avg Revenue beat(8)-6.4%

Revenue beat(12)6

Avg Revenue beat(12)-3.1%

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-94.8%

PT rev (3m)-94.8%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0.06%

Revenue NY rev (3m)0.06%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.34
P/FCF	N/A
P/OCF	N/A
P/B	0.64
P/tB	1.24
EV/EBITDA	N/A

EPS(TTM)-13.2

EYN/A

EPS(NY)-52.53

Fwd EYN/A

FCF(TTM)-4.85

FCFYN/A

OCF(TTM)-4.55

OCFYN/A

SpS7.2

BVpS3.8

TBVpS1.94

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-192.93%
ROE	-603.67%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	46.51%
FCFM	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.93%

GM growth 5Y0.67%

F-Score4

Asset Turnover0.61

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	31.79%
Cap/Sales	4.24%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.24
Quick Ratio	1.14
Altman-Z	-11.98

F-Score4

WACC9.06%

ROIC/WACCN/A

Cap/Depr(3y)39.05%

Cap/Depr(5y)93.91%

Cap/Sales(3y)4.44%

Cap/Sales(5y)8.08%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-29.41%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-1347.49%

EPS Next Y-329.17%

EPS Next 2Y-99.49%

EPS Next 3Y25.35%

EPS Next 5YN/A

Revenue 1Y (TTM)-28.48%

Revenue growth 3Y-3.43%

Revenue growth 5Y-13.01%

Sales Q2Q%-11.86%

Revenue Next Year22.44%

Revenue Next 2Y19.85%

Revenue Next 3Y5.77%

Revenue Next 5Y19.08%

EBIT growth 1Y22.19%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year54.46%

EBIT Next 3Y21.64%

EBIT Next 5YN/A

FCF growth 1Y39.58%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y40.69%

OCF growth 3YN/A

OCF growth 5YN/A

23ANDME HOLDING CO -CLASS A (ME) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens